Medtronic
Medtronic plc
Key figures
Period 2025-04-26 to 2026-04-24ConsolidatedU.S. GAAP
RevenueDisclosed
US$36.4B
Operating marginCalculated
17.8%
Net assets to total assetsCalculated
53.2%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
17.8%
Growth (revenue, 4-year average)
★★☆☆☆position among all companies
3.5%
Capital efficiency
★★★☆☆position among all companies
9.7%
Revenue and profit
Performance, financial position and capital allocation
Medtronic
Recent performance trends
Medtronic
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$31.7 billion | US$31.2 billion | US$32.4 billion | US$33.5 billion | US$36.4 billion |
| Operating income | US$5.8 billion | US$5.5 billion | US$5.1 billion | US$6.0 billion | US$6.5 billion |
| Net income | US$5.0 billion | US$3.8 billion | US$3.7 billion | US$4.7 billion | US$4.8 billion |
| Total assets | US$91.0 billion | US$90.9 billion | US$90.0 billion | US$91.7 billion | US$93.0 billion |
| Shareholders' equity | US$52.6 billion | US$51.5 billion | US$50.2 billion | US$48.0 billion | US$49.5 billion |
| Net cash provided by (used in) operating activities | US$7.3 billion | US$6.0 billion | US$6.8 billion | US$7.0 billion | US$7.3 billion |
| Net cash provided by (used in) investing activities | US$-1.7 billion | US$-3.5 billion | US$-2.4 billion | US$-1.9 billion | US$-2.9 billion |
| Net cash provided by (used in) financing activities | US$-5.3 billion | US$-5.0 billion | US$-4.5 billion | US$-4.4 billion | US$-4.8 billion |
| Cash and cash equivalents | US$3.7 billion | US$1.5 billion | US$1.3 billion | US$2.2 billion | US$1.9 billion |
Revenue scale in the same industry
Medtronic
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicThis companyFY Apr 2026 US$36.4B
- 4 MedlineFY Dec 2025 US$28.4B
- 5 StrykerFY Dec 2025 US$25.1B
- … 38 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$1.9 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-4.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-2.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$7.3 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$3.0 billion | Consolidated | Disclosed |
| Dividends paid | US$3.6 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$50.1 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.6 billion | Consolidated | Disclosed |
| Net assets | US$49.5 billion | Consolidated | Disclosed |
| Net sales | US$36.4 billion | Consolidated | Disclosed |
| Operating income | US$6.5 billion | Consolidated | Disclosed |
| Net income | US$4.8 billion | Consolidated | Disclosed |
| Total assets | US$93.0 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$1.0 billion | Consolidated | Disclosed |
| Operating margin | 17.8% | Consolidated | Calculated |
| Net assets to total assets | 53.2% | Consolidated | Calculated |
| Net margin | 13.2% | Consolidated | Calculated |
| Return on equity | 9.7% | Consolidated | Calculated |